Shelf life – Page 7 – Pharma.Tips

Bracketing Justification for Highest and Lowest Strengths: What Evidence Is Needed

Addressing Bracketing Justification for High and Low Strengths in Stability Studies The misuse of statistical approaches such as bracketing and matrixing during stability studies poses significant risks in pharmaceutical manufacturing.…

How to Use Ongoing Stability Data for Shelf-Life Extension

Leveraging Stability Data to Enhance Shelf-Life Management In the fast-paced world of pharmaceutical manufacturing, it is crucial to ensure the proper management of shelf-life through ongoing stability data. Ongoing stability…

How to Avoid Missing Critical Timepoints in Matrixing Designs

Preventing Issues with Timepoints in Matrixing Designs: A Practical Guide In the pharmaceutical industry, incorrect execution of bracketing and matrixing designs can lead to significant regulatory non-compliance during stability studies.…

Ongoing Stability Program Risks for Cold Chain Products

Identifying and Addressing Gaps in Ongoing Stability Programs for Cold Chain Products In pharmaceutical manufacturing, ensuring the stability of products throughout their intended shelf life is paramount, especially for cold…

Matrixing Misuse in Multi-Strength Tablet Stability Studies

Addressing Bracketing and Matrixing Misuse in Multi-Strength Tablet Stability Studies In the realm of pharmaceutical stability studies, bracketing and matrixing techniques play pivotal roles in ensuring that drug products maintain…

How to Manage Ongoing Stability for Products with Packaging Changes

Managing Ongoing Stability for Products Amidst Packaging Changes Maintaining product stability is critical for pharmaceutical manufacturers, especially when changes in packaging occur. Such modifications can lead to significant challenges in…

Bracketing Errors for Bottle and Blister Packaging Configurations

Addressing Bracketing Errors in Bottle and Blister Packaging Configurations In pharmaceutical manufacturing, the use of bracketing and matrixing strategies is vital for streamlined stability testing. However, errors in these configurations…

Ongoing Stability Gaps After Manufacturing Site Transfer

Addressing Ongoing Gaps in Stability Programs Following a Manufacturing Site Transfer The transfer of manufacturing sites in the pharmaceutical industry is a multi-faceted process that can often lead to ongoing…

How to Defend Reduced Stability Designs in CTD Module 3

In the highly regulated pharmaceutical landscape, ensuring the integrity and reliability of stability data is critical. One common challenge that arises is defending reduced stability designs in Common Technical Document…

How to Link Ongoing Stability Results with Change Control Decisions

Leveraging Stability Results for Informed Change Control Decisions In the pharmaceutical industry, ongoing stability program gaps can pose significant challenges to regulatory compliance and product quality. Practitioners often face the…

Bracketing and Matrixing Misuse in Generic Drug Submissions

Mitigating Bracketing and Matrixing Misuse in Generic Drug Submissions In the pharmaceutical sector, the proper execution of stability studies is crucial for ensuring the efficacy and safety of drug products.…

Ongoing Stability Program Deficiencies Found During FDA Inspections

Addressing Ongoing Gaps in Stability Programs Identified During FDA Inspections Ongoing stability program deficiencies can significantly impact regulatory compliance, product quality, and ultimately, patient safety. Recently, FDA inspections have highlighted…